Thirteen-year experience in lung transplantation for emphysema

Stephen D. Cassivi, Bryan F. Meyers, Richard J. Battafarano, Tracey J. Guthrie, Elbert P. Trulock, John P. Lynch, Joel D. Cooper, G. Alexander Patterson

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Background. Emphysema is the most common indication for lung transplantation. Recipients include younger patients with genetically determined alpha-1 antitrypsin deficiency (AAD) and, more commonly, patients with chronic obstructive pulmonary disease (COPD). We analyzed the results of our single-institution series of lung transplants for emphysema to identify outcome differences and factors predicting mortality and morbidity in these two groups. Methods. A retrospective analysis was undertaken of the 306 consecutive lung transplants for emphysema performed at our institution between 1988 and 2000 (220 COPD, 86 AAD). Follow-up was complete and averaged 3.7 years. Results. The mean age of AAD recipients (49 ± 6 years) was less than those with COPD (55 ± 6 years; p < 0.001). Hospital mortality was 6.2%, with no difference between COPD and AAD, or between single-lung transplants and bilateral-lung transplants. Hospital mortality during the most recent 6 years was significantly lower (3.9% vs 9.5%, p = 0.044). Five-year survival was 58.6% ± 3.5%, with no difference between COPD (56.8% ± 4.4%) and AAD (60.5% ± 5.8%). Five-year survival was better with bilateral-lung transplants (66.7% ± 4.0%) than with singlelung transplants (44.9% ± 6.0%, p < 0.005). Independent predictors of mortality by Cox analysis were single lung transplantation (relative hazard = 1.98, p < 0.001), and need for cardiopulmonary bypass during the transplant (relative hazard = 1.84, p = 0.038). Conclusions. AAD recipients, despite a younger age, do not achieve significantly superior survival results than those with COPD. Bilateral lung transplantation for emphysema results in better long-term survival. Accumulated experience and modifications in perioperative care over our 13-year series may explain recently improved early and long-term survival.

Original languageEnglish (US)
Pages (from-to)1663-1670
Number of pages8
JournalAnnals of Thoracic Surgery
Volume74
Issue number5
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

alpha 1-Antitrypsin Deficiency
Lung Transplantation
Emphysema
Chronic Obstructive Pulmonary Disease
Transplants
Lung
Hospital Mortality
Survival
Perioperative Care
Mortality
Cardiopulmonary Bypass
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Cassivi, S. D., Meyers, B. F., Battafarano, R. J., Guthrie, T. J., Trulock, E. P., Lynch, J. P., ... Patterson, G. A. (2002). Thirteen-year experience in lung transplantation for emphysema. Annals of Thoracic Surgery, 74(5), 1663-1670. https://doi.org/10.1016/S0003-4975(02)04064-X

Thirteen-year experience in lung transplantation for emphysema. / Cassivi, Stephen D.; Meyers, Bryan F.; Battafarano, Richard J.; Guthrie, Tracey J.; Trulock, Elbert P.; Lynch, John P.; Cooper, Joel D.; Patterson, G. Alexander.

In: Annals of Thoracic Surgery, Vol. 74, No. 5, 01.11.2002, p. 1663-1670.

Research output: Contribution to journalArticle

Cassivi, SD, Meyers, BF, Battafarano, RJ, Guthrie, TJ, Trulock, EP, Lynch, JP, Cooper, JD & Patterson, GA 2002, 'Thirteen-year experience in lung transplantation for emphysema', Annals of Thoracic Surgery, vol. 74, no. 5, pp. 1663-1670. https://doi.org/10.1016/S0003-4975(02)04064-X
Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, Lynch JP et al. Thirteen-year experience in lung transplantation for emphysema. Annals of Thoracic Surgery. 2002 Nov 1;74(5):1663-1670. https://doi.org/10.1016/S0003-4975(02)04064-X
Cassivi, Stephen D. ; Meyers, Bryan F. ; Battafarano, Richard J. ; Guthrie, Tracey J. ; Trulock, Elbert P. ; Lynch, John P. ; Cooper, Joel D. ; Patterson, G. Alexander. / Thirteen-year experience in lung transplantation for emphysema. In: Annals of Thoracic Surgery. 2002 ; Vol. 74, No. 5. pp. 1663-1670.
@article{e5e9e26695c040f4b13faa40d6e30788,
title = "Thirteen-year experience in lung transplantation for emphysema",
abstract = "Background. Emphysema is the most common indication for lung transplantation. Recipients include younger patients with genetically determined alpha-1 antitrypsin deficiency (AAD) and, more commonly, patients with chronic obstructive pulmonary disease (COPD). We analyzed the results of our single-institution series of lung transplants for emphysema to identify outcome differences and factors predicting mortality and morbidity in these two groups. Methods. A retrospective analysis was undertaken of the 306 consecutive lung transplants for emphysema performed at our institution between 1988 and 2000 (220 COPD, 86 AAD). Follow-up was complete and averaged 3.7 years. Results. The mean age of AAD recipients (49 ± 6 years) was less than those with COPD (55 ± 6 years; p < 0.001). Hospital mortality was 6.2{\%}, with no difference between COPD and AAD, or between single-lung transplants and bilateral-lung transplants. Hospital mortality during the most recent 6 years was significantly lower (3.9{\%} vs 9.5{\%}, p = 0.044). Five-year survival was 58.6{\%} ± 3.5{\%}, with no difference between COPD (56.8{\%} ± 4.4{\%}) and AAD (60.5{\%} ± 5.8{\%}). Five-year survival was better with bilateral-lung transplants (66.7{\%} ± 4.0{\%}) than with singlelung transplants (44.9{\%} ± 6.0{\%}, p < 0.005). Independent predictors of mortality by Cox analysis were single lung transplantation (relative hazard = 1.98, p < 0.001), and need for cardiopulmonary bypass during the transplant (relative hazard = 1.84, p = 0.038). Conclusions. AAD recipients, despite a younger age, do not achieve significantly superior survival results than those with COPD. Bilateral lung transplantation for emphysema results in better long-term survival. Accumulated experience and modifications in perioperative care over our 13-year series may explain recently improved early and long-term survival.",
author = "Cassivi, {Stephen D.} and Meyers, {Bryan F.} and Battafarano, {Richard J.} and Guthrie, {Tracey J.} and Trulock, {Elbert P.} and Lynch, {John P.} and Cooper, {Joel D.} and Patterson, {G. Alexander}",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S0003-4975(02)04064-X",
language = "English (US)",
volume = "74",
pages = "1663--1670",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Thirteen-year experience in lung transplantation for emphysema

AU - Cassivi, Stephen D.

AU - Meyers, Bryan F.

AU - Battafarano, Richard J.

AU - Guthrie, Tracey J.

AU - Trulock, Elbert P.

AU - Lynch, John P.

AU - Cooper, Joel D.

AU - Patterson, G. Alexander

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Background. Emphysema is the most common indication for lung transplantation. Recipients include younger patients with genetically determined alpha-1 antitrypsin deficiency (AAD) and, more commonly, patients with chronic obstructive pulmonary disease (COPD). We analyzed the results of our single-institution series of lung transplants for emphysema to identify outcome differences and factors predicting mortality and morbidity in these two groups. Methods. A retrospective analysis was undertaken of the 306 consecutive lung transplants for emphysema performed at our institution between 1988 and 2000 (220 COPD, 86 AAD). Follow-up was complete and averaged 3.7 years. Results. The mean age of AAD recipients (49 ± 6 years) was less than those with COPD (55 ± 6 years; p < 0.001). Hospital mortality was 6.2%, with no difference between COPD and AAD, or between single-lung transplants and bilateral-lung transplants. Hospital mortality during the most recent 6 years was significantly lower (3.9% vs 9.5%, p = 0.044). Five-year survival was 58.6% ± 3.5%, with no difference between COPD (56.8% ± 4.4%) and AAD (60.5% ± 5.8%). Five-year survival was better with bilateral-lung transplants (66.7% ± 4.0%) than with singlelung transplants (44.9% ± 6.0%, p < 0.005). Independent predictors of mortality by Cox analysis were single lung transplantation (relative hazard = 1.98, p < 0.001), and need for cardiopulmonary bypass during the transplant (relative hazard = 1.84, p = 0.038). Conclusions. AAD recipients, despite a younger age, do not achieve significantly superior survival results than those with COPD. Bilateral lung transplantation for emphysema results in better long-term survival. Accumulated experience and modifications in perioperative care over our 13-year series may explain recently improved early and long-term survival.

AB - Background. Emphysema is the most common indication for lung transplantation. Recipients include younger patients with genetically determined alpha-1 antitrypsin deficiency (AAD) and, more commonly, patients with chronic obstructive pulmonary disease (COPD). We analyzed the results of our single-institution series of lung transplants for emphysema to identify outcome differences and factors predicting mortality and morbidity in these two groups. Methods. A retrospective analysis was undertaken of the 306 consecutive lung transplants for emphysema performed at our institution between 1988 and 2000 (220 COPD, 86 AAD). Follow-up was complete and averaged 3.7 years. Results. The mean age of AAD recipients (49 ± 6 years) was less than those with COPD (55 ± 6 years; p < 0.001). Hospital mortality was 6.2%, with no difference between COPD and AAD, or between single-lung transplants and bilateral-lung transplants. Hospital mortality during the most recent 6 years was significantly lower (3.9% vs 9.5%, p = 0.044). Five-year survival was 58.6% ± 3.5%, with no difference between COPD (56.8% ± 4.4%) and AAD (60.5% ± 5.8%). Five-year survival was better with bilateral-lung transplants (66.7% ± 4.0%) than with singlelung transplants (44.9% ± 6.0%, p < 0.005). Independent predictors of mortality by Cox analysis were single lung transplantation (relative hazard = 1.98, p < 0.001), and need for cardiopulmonary bypass during the transplant (relative hazard = 1.84, p = 0.038). Conclusions. AAD recipients, despite a younger age, do not achieve significantly superior survival results than those with COPD. Bilateral lung transplantation for emphysema results in better long-term survival. Accumulated experience and modifications in perioperative care over our 13-year series may explain recently improved early and long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=0036839848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036839848&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(02)04064-X

DO - 10.1016/S0003-4975(02)04064-X

M3 - Article

C2 - 12440627

AN - SCOPUS:0036839848

VL - 74

SP - 1663

EP - 1670

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -